Preview Newsletter
XARELTO Media Monitoring – Week of 01-22-16
-
South Florida Woman Files Wrongful Death Xarelto Lawsuit Over Husband's Fatal Bleed
Jan 16, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) claiming that the blood thinner they manufacture caused wrongful death. The suit was initially filed in south Florida by the widow of the deceased man, claiming that Xarelto manufacturers neglected to adequately warn patients about the significant bleeding risks connected to their anticoagulant. The plaintiff alleges that the drug is to blame for her husband’s death, which occurred after he suffered from an episode of uncontrollable internal bleeding that doctors could not stop. -
Xarelto Lawsuit Claims Blood Thinner Caused Georgia Man's Uncontrollable Internal Bleeding Death
Jan 18, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has joined the over 2,800 cases federally filed in Xarelto multidistrict litigation (MDL No.2592). The case was filed in the Eastern District of Louisiana, where the MDL is being held, under complaint number 2:15-cv-00885. It was filed on behalf of a Georgia father by his son, after the man had unexpectedly passed away. According to the son’s allegations, the man died due to an uncontrollable internal bleeding episode caused by Xarelto. The lawsuit has been filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals (a division of the well-known corporation Johnson & Johnson). -
Xarelto Lawsuit Plaintiffs Say 4 Years Without An Available Antidote Is Reckless And Negligent
Jan 18, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on comments from Xarelto plaintiffs who are drawing greater attention to the fact that the anticoagulant has now been on the market for 4 years without the development of any corresponding antidote. They claim that this shows recklessness and negligence on the part of the drug’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of pharmaceutical giant Johnson & Johnson). -
Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials
Jan 18, 2016 | MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, reports today that Xarelto lawsuits have risen to approximately 2,400 cases against Bayer and Johnson & Johnson's Janssen Pharmaceutical Division as the court has started the process of selecting cases for the initial bellwether trials. 40 cases will be selected for the Xarelto multidistrict litigation bellwether trial pool. The Xarelto multidistrict litigation (MDL) is currently underway in the U.S. District Court in the Eastern District of Louisiana. A court order instructed both the plaintiffs and defense to each select 10 cases for the pool by January 11th, five from the Eastern District of Louisiana, one from Mississippi, one from Texas, and three from other states. -
Xarelto Lawsuit Plaintiffs Observe Trial Result Questioning Due To Defective Blood Clot Measurement Device
Jan 20, 2016 | Blood Thinner Help
BloodThinnerHelp.com reports on news shared by Reuters which may impact the many lawsuits filed against Bayer AG and Janssen Pharmaceuticals; manufacturers of blood-thinning drug Xarelto. According to the article, both American and European drug regulators have begun research to determine whether a defective blood-clotting test device called an International Normalized Ration may have influenced the outcome of multiple trial results on the drug. -
Xarelto Lawsuit From Texas Claims Manufacturers Failed To Warn Consumers Of Drug's Dangerous Side Effects
Jan 20, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit filed against manufacturers Bayer AG and Janssen Phamaceuticals in reference to their blood thinning drug Xarelto. The claim was filed in the Eastern District of New York under number 1:14-cv-04524 but involves a woman from Texas who alleges that Xarelto manufacturers failed to properly warn consumers about the substantial risks associated with their anticoagulant. -
Xarelto Lawsuit Plaintiff Questions Effectiveness Of Blood Thinner’s Once-Daily Dosage
Jan 21, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on a Xarelto lawsuit filed in Pennsylvania State Court which brings new allegations to light. The suit, filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson), is especially notable due to the fact that it discusses something that the other mounting Xarelto lawsuits do not. It alleges that the recommended one pill per day dosing of the drug is ineffective for a full 24-hours as the company has indicated. -
Xarelto Lawsuit Plaintiff Alleges Blood Thinner Caused Fatal Parenchymal Hemorrhage Of Vermont Manl
Jan 21, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against pharmaceutical manufactureres Janssen Pharmaceuticals and Bayer AG regarding their blood thinning drug, Xarelto. The suit is just one of over 2,800 federally-filed cases which all synonymously claim that the anticoagulant can cause dangerous uncontrollable bleeding episodes which often result in severe and permanent injuries or death. -
Xarelto Bleeding Lawsuit Filed Over Internal Bleeding Death
Jan 20, 2016 | Top Class Actions
By Robert J. Boumis
A group of four living plaintiffs have joined the mass legal action over alleged Xarelto bleeding deaths. Among the Xarelto lawsuits is a family suing on behalf of Mary B. who allegedly died from Xarelto complications. -
Xarelto Bleed Injury Timeline 2016, Lawsuit Updates, and Patient Information
Jan 15, 2016 | Lieff Cabraser Heimann & Bernstein
By Lieff Cabraser
The Xarelto multidistrict bellwether litigation is moving forward in the U.S. District Court in the Eastern District of Louisiana. The Court asked the parties in late December 2015 to select pool cases, which selection was completed January 11, 2016. The Court also requested that the chosen cases reflect multiple Xarelto injury categories, including gastrointestinal bleed and gi bleeding, brain bleeding events, hemorrhages, and hemorrhagic strokes. The Court is expected to select additional cases for inclusion originating in multiple states. The first trials are set for early February 2017 in Louisiana, with subsequent trials to occur in Mississippi and Texas in April and May 2017. -
Xarelto Lawyer California
Jan 17, 2016 | Law Office of J. Chrisp
When it comes to medication, patients generally take what is prescribed hoping for a quick recovery or remedy for their pain or illness. We don’t usually expect to find out our medication is defective. When this happens, patients who are treated with defective drugs can often seek compensation for their pain and suffering and other damages stemming from using the medication. Although this can occur with a wide variety of medications on the market, Xarelto is one that may require the assistance of a lawyer in California. -
Xarelto Bleeding Precautions
Jan 18, 2016 | Schmidt National Law Group
The main risk associated with Xarelto (rivaroxaban) is uncontrolled bleeding, so employing some effective Xarelto bleeding precautions is of paramount importance for all patients taking this medication. If you are taking Xarelto to treat or prevent any condition such as Atrial Fibrillation (AFib), Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), or as a prophylaxis against stroke and blood clots, you should be adequately warned about the risks associated with this medication. Depending on what your condition is, you may need to take Xarelto for a defined period (usually for 2-6 weeks) or indefinitely for the rest of your life. Always read through the drug label information to know all the side effects and contraindications of this medication, and check with your doctor or pharmacist in case of any symptom of Xarelto side effects. -
Xarelto: The Impending Investigations
Jan 18, 2016 | Xarelto Lawyer
For patients who have experienced medical conditions that required being prescribed blood thinners, the results have been less than stellar. In fact, many times the results have been catastrophic. According to the Food and Drug Administration, the latest figures show over 2,000 Xarelto patients have experienced complications. With more than 200 deaths having been directly attributed to Xarelto complications, more legal experts familiar with the situation are now expecting an influx of lawsuits from numerous states, such as Florida and Vermont. In recent months, a Florida man died of a subdural hemorrhage, while a Vermont patient died from uncontrolled bleeding after taking Xarelto for only 10 days. -
Finally a Xarelto Antidote seems to be a reality
Jan 21, 2016 | Schmidt National Law Group
Almost three hundreds of Xarelto lawsuits have been filed up to now. The amount of plaintiffs who seek the help of a Xarelto attorney to ask for compensation from Janssen Pharmaceutical and Bayer AG just reached over 2,800 cases. The huge and ever-growing number of Xarelto lawsuits has been recently consolidated in a Multidistrict Litigation MDL No. 2592 in the Eastern District of Louisiana, overseen by Judge Eldon Fallon. -
Researchers Question Results of Clinical Trial Used to Approve Xarelto
Jan 21, 2016 | The Legal Examiner
By Eric T. Chaffin
The FDA first approved Xarelto (rivaroxaban) on July 1, 2011. A few months later, Thomas M. Burton, writing for the Wall Street Journal, noted that though the drug had been approved, it was despite the fact that FDA staff had found flaws in the clinical studies submitted by the manufacturer. -
Xarelto Blood Thinner MDL Reaches 2,400 Lawsuits
Jan 22, 2016 | Top Class Actions
By Ashley Vanover
Blood thinner lawsuits alleging patients suffered serious and life-threatening internal bleeding events after using the blood thinner Xarelto show no signs of slowing down, with 2,400 Xarelto lawsuits now pending in the multidistrict litigation.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
-
South Florida Woman Files Wrongful Death Xarelto Lawsuit Over Husband's Fatal Bleed
Jan 16, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) claiming that the blood thinner they manufacture caused wrongful death. The suit was initially filed in south Florida by the widow of the deceased man, claiming that Xarelto manufacturers neglected to adequately warn patients about the significant bleeding risks connected to their anticoagulant. The plaintiff alleges that the drug is to blame for her husband’s death, which occurred after he suffered from an episode of uncontrollable internal bleeding that doctors could not stop.
Xarelto was approved in 2011 by the U.S. Food and Drug Administration, and its initial popularity skyrocketed as it was deemed a revolutionary new type of blood thinner. While traditional blood thinners had required consumers to go through regular monitoring, dosage adjustments, and special diets, Xarelto required none of these things. The benefits may have helped consumers to ignore one much more understated fact which plaintiffs bring up repeatedly today: Xarelto was released to the market without any corresponding antidote for emergency bleeding situations.
Because Xarelto has no available antidote, when a patient taking the drug is injured and begins to bleed, there is no way to clot their blood. This can turn even a minor injury into a dangerous one. In these situations, physicians are required to use extreme life saving measures such as surgeries to relieve pressure from pooling blood or blood transfusions to attempt to keep the patient from bleeding out.
Traditional blood thinners–those which do require a special diet, do so because they have an available antidote through vitamin K. If a patient taking a traditional blood thinner becomes injured and begins to bleed, physicians can administer vitamin K to counteract the blood thinning effects of the drug and allow their blood to clot. This antidote can easily become the difference between life and death in emergency situations, and Xarelto patients have none available.
Perhaps due to this reason, Xarelto has now become the topic of over 2,800 lawsuits filed in federal court, as well as another 500 cases which have been consolidated in a mass tort group by the Court of Common Pleas in Philadelphia, PA.
The lawsuit filed by this particular widow was initially filed in Florida under case number 9:14-cv-80831 before being transferred to the Eastern District of Louisiana during multidistrict litigation consolidation. It has now become a part of multidistrict litigation No. 2592, and is being overseen by the Honorable Judge Eldon Fallon. This consolidation was possible due to an order by the U.S. Judicial Panel on Multidistrict Litigation, which transfers the mounting, similar lawsuits to a single court to help fast track litigation processes.
Within information in her lawsuit, the widow explains that her husband was using Xarelto to treat his atrial fibrillation; a common heart condition that can increase a patient’s risk of stroke. The Xarelto was intended to prevent any potential strokes for the man, however, while using the drug, he suddenly suffered from a subdural hemorrhage and passed away when physicians could not get the brain bleed to stop.
Attorney Joseph Osborne is currently working to help ensure that everyone who has been negatively affected by the Xarelto, as this widow has, will have the opportunity to evaluate their legal rights. These individuals may be entitled to legal action and significant compensation. At this time, Attorney Osborne is offering free consultations for those affected.
To request additional information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.12newsnow.com/story/30981902/south-florida-woman-files-wrongful-death-xarelto-lawsuit-over-husbands-fatal-bleed
-
Xarelto Lawsuit Claims Blood Thinner Caused Georgia Man's Uncontrollable Internal Bleeding Death
Jan 18, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has joined the over 2,800 cases federally filed in Xarelto multidistrict litigation (MDL No.2592). The case was filed in the Eastern District of Louisiana, where the MDL is being held, under complaint number 2:15-cv-00885. It was filed on behalf of a Georgia father by his son, after the man had unexpectedly passed away. According to the son’s allegations, the man died due to an uncontrollable internal bleeding episode caused by Xarelto. The lawsuit has been filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals (a division of the well-known corporation Johnson & Johnson).
In addition to this ever-growing number of federal court lawsuits filed against Xarelto, there is a Mass Tort Group of over 550 cases which was consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania. Consolidations like these take place in order to help legal proceedings run smoothly and efficiently, avoiding duplicate discovery or different rulings from multiple judges. Additionally, consolidations help to conserve the resources of everyone involved.
Court documentation for this particular lawsuit indicates that it was filed on March 20th of 2015, and details show that the father had been prescribed Xarelto by a family doctor in order to treat his atrial fibrillation condition. Atrial fibrillation is a common heart condition which generally causes the heart to beat faster than normal, and can put patients at greater risk for strokes. Preventatively, many people with this condition are prescribed blood thinning drugs.
The plaintiff indicates that he and his father were not made aware of the serious dangers associated with Xarelto, specifically the fact that it has no corresponding antidote for emergency situations. Had they known this information, the son says that they would have chosen an alternative blood thinner, such as warfarin. Though Xarelto has now been on the market for over four years, manufacturers have yet to provide an antidote for the drug.
Without an antidote, if a patient taking Xarelto suffers even a minor injury and begins to bleed, physicians will be unable to stop that bleed and clot their blood. In these situations, doctors must resort to extreme, life-saving treatments such as surgery or blood transfusions.
Traditional blood thinners do not come with the same risk; they have an antidote available through vitamin K. When a patient taking a traditional blood thinner becomes injured and bleeds, doctors are able to treat them with vitamin K, which counteracts the medicine’s effects and clots their blood. This antidote can make a huge difference in emergency situations; possibly the difference between life and death, especially for the plaintiff’s father in this particular case.
Attorney Joseph Osborne is now working to ensure that everyone who has taken Xarelto and has subsequently suffered from adverse health events will have the opportunity to evaluate their legal rights. These people may be entitled to significant compensation. Currently, Attorney Osborne is offering free consultations to those affected as they pursue justice.
To ask questions or request additional information, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/30989672/xarelto-lawsuit-claims-blood-thinner-caused-georgia-mans-uncontrollable-internal-bleeding-death
-
Xarelto Lawsuit Plaintiffs Say 4 Years Without An Available Antidote Is Reckless And Negligent
Jan 18, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on comments from Xarelto plaintiffs who are drawing greater attention to the fact that the anticoagulant has now been on the market for 4 years without the development of any corresponding antidote. They claim that this shows recklessness and negligence on the part of the drug’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of pharmaceutical giant Johnson & Johnson).
The federally-filed Xarelto bleeding lawsuits that now number over 2,800 cases are currently going through the process of bellwether trial selection, and have been consolidated to form MDL No. 2592 by the U.S. Judicial Panel on Multidistrict Litigation. They are being housed in the Eastern District of Louisiana and overseen by Judge Eldon Fallon.
Plaintiffs involved in the lawsuits state that this alarming lack of antidote is a very dangerous issue for anyone using the drug. It means that when someone with Xarelto in their system becomes injured and bleeds, doctors will not be able to clot their blood. In these circumstances, doctors must resort to extreme life-saving tactics such as blood transfusions to prevent the loss of too much blood, or surgeries to relieve pressure from internal pooling of blood.
Traditional blood thinners do not have this same issue. When they were released to the market for consumer use, they were released with a corresponding antidote, which plaintiffs claim is a difference they wish they had been made aware of. When patients taking traditional blood thinners become injured and bleed, they can be treated with vitamin K, which will reverse the effects of the blood thinner and clot their blood. This antidote can be the single difference between life or death for those involved in emergency situations.
Xarelto gained approval by the U.S. Food and Drug Administration in 2011, and was intended to be a drug which could prevent deep vein thrombosis and clotting for patients who had undergone hip or knee replacement surgeries. Several months later, it was additionally approved to treat patients suffering from atrial fibrillation; a common heart condition which can put people at increased risk for stroke.
Despite the ever-growing number of Xarelto bleeding lawsuits, however, the drug has remained at the top of the list of most commonly used blood thinners. Plaintiffs involved in today’s lawsuits indicate that manufacturers use misleading marketing tactics, which make users unaware of the significant dangers associated with the drug. Several lawsuits in the current MDL were filed on behalf of someone by family members of that person, who passed away due to uncontrollable bleeding while taking Xarelto.
Attorney Joseph Osborne is now working to help ensure that everyone negatively affected by the blood thinner will have the opportunity to fully explore their legal rights. Those who suffered from adverse health events after using Xarelto may be entitled to legal action and compensation. At this time, Attorney Osborne is offering complimentary legal consultations for affected persons.
To ask questions or request further information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.hometownstations.com/story/30989675/xarelto-lawsuit-plaintiffs-say-4-years-without-an-available-antidote-is-reckless-and-negligent
-
Jan 18, 2016 | MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, reports today that Xarelto lawsuits have risen to approximately 2,400 cases against Bayer and Johnson & Johnson's Janssen Pharmaceutical Division as the court has started the process of selecting cases for the initial bellwether trials. 40 cases will be selected for the Xarelto multidistrict litigation bellwether trial pool. The Xarelto multidistrict litigation (MDL) is currently underway in the U.S. District Court in the Eastern District of Louisiana. A court order instructed both the plaintiffs and defense to each select 10 cases for the pool by January 11th, five from the Eastern District ofLouisiana, one from Mississippi, one from Texas, and three from other states. The court order also asked the parties to try to choose at least one case from six different injury categories. The injury categories include gastrointestinal bleed, brain bleed/hemorrhagic stroke, and rectal bleeding, and the court order is requesting cases of individuals who suffered these injuries while using Xarelto to prevent stroke, as well as individuals who used Xarelto to treat pulmonary embolism or deep vein thrombosis. Additionally, they had to select an additional 20 lawsuits by January 15th including 10 cases from Louisiana, two from Mississippi, and one case each from eight other states. Four bellwether trials are set to begin in February of 2017. The first two trials are set to take place in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017. The third and fourth trials will take place in Mississippi and Texas on April 24th, 2017 and May 30th, 2017.
Court records now indicate that approximately 2,400 Xarelto cases are pending in the Eastern District ofLouisiana against Xarelto's maker, Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division. The lawsuits have similar allegations, claiming serious health problems, long hospital stays, and even death as a result of uncontrollable bleeding events due to Xarelto usage. There is no known antidote at this time. MTS also announced today that they have secured large capital for Xarelto funding. They are also reporting that they are able to provide assistance for Xarelto bleeding victims, or their loved ones, who are in need of an attorney.
MTS encourages anyone who is looking for lawsuit funding on their Xarelto or Pradaxa case, or anyone looking for assistance with finding a Xarelto or Pradaxa law firm or lawyer, to contact the company immediately for assistance. If you, or a loved one, need assistance, please visit the company's website athttp://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases for more information.
Chris Janish, CEO of MTS, commented on the recent announcement, "We urge victims or their family members who have been hospitalized due to uncontrollable bleeding events while taking Xarelto to contact us as the litigation is picking up steam and time is running out to file a claim. We are able to connect people with some of the most highly recognized Xarelto law firms that we work with to assist them with their cases."
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can help you. Victims of Pradaxa or Xarelto usage and complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit:http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have been injured by Xarelto or Pradaxa and need lawsuit money or lawsuit help, including finding a Xarelto or Pradaxa law firm, and would like to speak with a live agent who can answer any questions you may have, please call: 877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.com and an agent will contact you shortly.
Disclaimer: MT Services LLC, operator of Lawsuitsettlementnews.com, is not a law firm and cannot provide legal advice on your case; however, MTS works with lawyers involved in mass tort litigations who are willing to provide a free legal consultation at the consumer's request. For a list of full disclosures please visit the company's website disclosure page.
http://www.prnewswire.com/news-releases/lawsuitsettlementnewscom-says-xarelto-lawsuits-rise-as-court-begins-process-to-select-cases-for-initial-bellwether-trials-300205539.html
-
Jan 20, 2016 | Blood Thinner Help
BloodThinnerHelp.com reports on news shared by Reuters which may impact the many lawsuits filed against Bayer AG and Janssen Pharmaceuticals; manufacturers of blood-thinning drug Xarelto. According to the article, both American and European drug regulators have begun research to determine whether a defective blood-clotting test device called an International Normalized Ration may have influenced the outcome of multiple trial results on the drug.
Xarelto has been in the news frequently of late; the drug is the subject of over 2,800 federal court lawsuits which commonly claim that the anticoagulant causes dangerous and potentially fatal uncontrollable bleeding episodes. These federally-filed lawsuits were consolidated by the U.S. Judicial Panel on Multidistrict Litigation. They now form MDL No. 2592 in the Eastern District of Louisiana, where they are being overseen by the Honorable Judge Eldon Fallon.
Additionally, these Xarelto lawsuits are joined by another group of more than 500 lawsuits alleging much the same, which have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort group.
This attention prompted further Xarelto studies, which often compare the new type of blood thinner to more traditional blood thinners such as warfarin. This particular test, the results of which are now being questioned, was designed to evaluate the overall effectiveness of each blood thinner for preventing strokes in patients suffering from atrial fibrillation, a common heart condition that puts patients at increased risk of stroke. It is now being reported, however, that during this testing, results may have been altered because of a defect in one of the International Normalized Ration (INR) devices which was used.
The European Medicines Agency commented on this possibility, stating, “Due to the defect, it is now thought that the INR device may have impacted the clotting results in some patients in the warfarin group.” They noted that complete results of the study would be published after their investigation had been completed. INR devices measure how quickly blood is able to clot. Unfortunately, the system used for this particular study was apparently recalled in December of 2014 when researchers noticed a study’s significantly low results.
While plaintiffs involved in the Xarelto MDL and the mass tort grouping anxiously await trial, Attorney Joseph Osborne is attempting to help ensure that everyone who has been negatively affected after taking the blood thinner will have the opportunity to fully explore their legal rights. Those who used Xarelto and later suffered from adverse health or bleeding events may be entitled to compensation. At this time, Attorney Osborne is offering complimentary Xarelto consultations to affected individuals.
To request further information regarding the Xarelto bleeding lawsuits, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.foxwilmington.com/story/31007696/xarelto-lawsuit-plaintiffs-observe-trial-result-questioning-due-to-defective-blood-clot-measurement-device
-
Jan 20, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.comreports on the details of a lawsuit filed against manufacturers Bayer AG and Janssen Phamaceuticals in reference to their blood thinning drug Xarelto. The claim was filed in the Eastern District of New York under number 1:14-cv-04524 but involves a woman from Texas who alleges that Xarelto manufacturers failed to properly warn consumers about the substantial risks associated with their anticoagulant.
Further details of the woman’s lawsuit indicate that she was prescribed Xarelto in order to treat her atrial fibrillation condition; a common heart condition which puts patients at increased risk for stroke. The woman notes that in her case, however, she had only taken the blood thinner about 5 months before suddenly suffering a life-threatening internal bleed which has left her in need of long-term medical care.
Xarelto was approved by the U.S. Food and Drug Administration in 2011. Initially, it was very popular as it did not require regular monitoring by physicians or dosage adjustments as other blood thinners did, and it did not require specific diets. This excitement over the new type of anticoagulant did not last long, however, as consumers started to realize that the drug had been released to the market without any accompanying antidote.
Suddenly, many consumers began to consider the drug incredibly dangerous. Its lack of antidote meant that those taking the blood thinner who suffered injuries and began to bleed were at an especially great risk for bleeding out, as physicians would be unable to use anything to counteract the effects of the drug and clot their blood. Although many indicate that manufacturers have been working on developing an antidote for years now, the companies have made none available to the public at this time. Plaintiffs involved in current Xarelto lawsuits from across the nation say that the manufacturers were both reckless and negligent to have released this type of drug without any antidote option.
The lack of antidote creates emergency situations where physicians must resort to life-saving treatments such as surgeries or blood transfusions. It is an issue that people taking traditional blood thinners do not have to deal with. These blood thinners have a corresponding antidote through vitamin K, therefore, if a patient taking a traditional blood thinner begins to bleed, physicians can treat them with vitamin K to reverse the blood thinner’s effects and clot their blood. This seemingly small difference can save lives in emergency situations.
Patients who use traditional blood thinners do not have the same issue. They have an available antidote in vitamin K. This means that when a patient taking a traditional blood thinner is injured and bleeding, physicians are able to treat them with vitamin K, counteracting the effects of the drug and allowing their blood to clot. In certain bleeding injuries, this antidote can mean the difference of life or death.
Today, lawsuits filed against Xarelto manufacturers which commonly allege that the drug causes dangerous uncontrollable bleeding episodes, number around 2,800 federal cases. These cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592and are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana.
Attorney Joseph Osborne is now working to help ensure that everyone affected by Xarelto will have the opportunity to fully explore their legal rights. Patients who took the blood thinner and later suffered from adverse health events may be entitled to legal action and significant compensation. Attorney Osborne is currently offering free legal consultations to affected individuals.
To request additional information on Xarelto bleeding lawsuits or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.wdrb.com/story/31017686/xarelto-lawsuit-from-texas-claims-manufacturers-failed-to-warn-consumers-of-drugs-dangerous-side-effects
-
Xarelto Lawsuit Plaintiff Questions Effectiveness Of Blood Thinner’s Once-Daily Dosage
Jan 21, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on a Xarelto lawsuit filed in Pennsylvania State Court which brings new allegations to light. The suit, filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson), is especially notable due to the fact that it discusses something that the other mounting Xarelto lawsuits do not. It alleges that the recommended one pill per day dosing of the drug is ineffective for a full 24-hours as the company has indicated.
Supporting evidence of this claim is found within further details of the complaint, which surround a plaintiff who suffered from a stroke just four days after initially taking Xarelto specifically to prevent a stroke due to his atrial fibrillation condition. Atrial fibrillation is a common heart condition which generally causes the heart to beat more rapidly than normal, and it can put patients at increased risk for stroke. Many patients with this condition turn to the help of blood thinners as a preventative measure.
Xarelto, however, is unlike other blood thinners on the market today with its one pill per day dosing. The dose is also indicated to be one-size-fits-all. While all other blood thinners require 2 doses of medication daily, Xarelto is the only blood thinner to have offered just one.
After suffering from a debilitating stroke, the plaintiff filed his lawsuit against Xarelto manufacturers on October 8, 2015. Despite the fact that his lawsuit was the first of its kind, there have been many other cases filed against Xarelto manufacturers alleging that the drug has dangerous and potentially deadly side effects.
Details found within the court documents of this lawsuit show that the plaintiff not only states that the drug was ineffective in preventing his stroke, but he also claims that Xarelto may have caused his stroke. Across the U.S., Xarelto has become the subject of more than 2,800 federal lawsuits and over 550 additional suits in a mass tort group in Pennsylvania.
In 2011, Xarelto was approved by the U.S. Food and Drug Administration to prevent strokes and blood clots for individuals with atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. The anticoagulant was intended to help ensure that these patients don’t develop deep vein thrombosis (DVT) or pulmonary embolism during their recovery period.
Initially, many customers were excited to use Xarelto because unlike traditional blood thinners, it did not require regular evaluations and dosage adjustments by a doctor, or any specific diet. One major problem that has been noted with the blood thinner, however, is that it was released to the market for sale without any accompanying antidote. Those who use the drug and begin to bleed from even minor injuries may be unable to get their blood to clot. Doctors treating patients in this situation resort to life-saving measures such as blood transfusions or surgeries.
Traditional blood thinners are very different in this way, as well. The blood thinning effects of these medications are able to be reversed with vitamin K. If someone using a traditional blood thinner begins to bleed, doctors treat them with vitamin K, which allows their blood to clot, and potentially saves their life.
At this time, all Xarelto lawsuits filed in federal court have been consolidated to form MDL number 2592. These cases are being overseen by U.S. District Judge Eldon E. Fallon. It is fully anticipated that as the MDL cases await bellwether trials, additional lawsuits will be filed against the anticoagulant.
Attorney Joseph Osborne is currently working to help ensure that individuals suffering after using Xarelto will all be able to explore their legal rights. He is offering free consultations to those involved, who may be entitled to significant compensation.
To request additional information or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2810955#ixzz3y0Q0lP32
-
Xarelto Lawsuit Plaintiff Alleges Blood Thinner Caused Fatal Parenchymal Hemorrhage Of Vermont Manl
Jan 21, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against pharmaceutical manufactureres Janssen Pharmaceuticals and Bayer AG regarding their blood thinning drug, Xarelto. The suit is just one of over 2,800 federally-filed cases which all synonymously claim that the anticoagulant can cause dangerous uncontrollable bleeding episodes which often result in severe and permanent injuries or death.
The suit was filed under case number 2:14-cv-00159-cr in a Vermont federal court on July 25th, 2014. The plaintiff is a daughter who is suing on behalf of her father, who has passed away unexpectedly after suffering from a brain bleed called a parenchymal hemorrhage which his family alleges was caused by the Xarelto that was in his system at the time of his death. Because Xarelto thins the blood in patients, the physicians at the hospital were unable to clot the father’s blood in order to prevent him from losing too much too quickly.
Because Xarelto was released to the market without any corresponding antidote, doctors were unable to counter its blood thinning effects during this dangerous emergency situation. Even a minor bleeding injury can cause the same problem because of the lack of antidote, a fact that many plaintiffs involved in current Xarelto lawsuits call reckless and negligent on the part of the manufacturers.
Traditional blood thinners do not have the same issue, as they offer an antidote through vitamin K. When patients taking these traditional blood thinners, (such as warfarin) begin to bleed, physicians are able to more quickly reverse the effects of the blood thinner by treating patients with vitamin K, which will clot their blood. This antidote can mean the difference between life and death for many, and is something that the current plaintiff desperately wishes her father had available to him during his time of need.
Xarelto has now become the subject of over 2,800 federal court lawsuits, and the subject of yet another 550 cases consolidated in a mass tort group in Philadelphia. The federal court cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form multidistrict litigation number 2592 and currently await legal proceedings. These consolidations are possible due to the fact that all lawsuits contain similar allegations filed against the same defendants. The process will help to fast track litigation and save time and finances for everyone involved.
At this time, attorney Joseph Osborne is working to help ensure that anyone who has suffered from adverse health effects after using Xarelto will have the ability to fully explore their legal rights. These people may be entitled to compensation. Currently, Attorney Osborne is offering complimentary consultations to those who have been negatively affected.
To obtain additional information or ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2809415#ixzz3y0QI6Crz
-
Xarelto Bleeding Lawsuit Filed Over Internal Bleeding Death
Jan 20, 2016 | Top Class Actions
By Robert J. Boumis
A group of four living plaintiffs have joined the mass legal action over alleged Xarelto bleeding deaths.
Among the Xarelto lawsuits is a family suing on behalf of Mary B. who allegedly died from Xarelto complications.
According to the Xarelto bleeding lawsuit, Mary took Xarelto from 2013 until early 2015 when she suffered from massive internal bleeding.
Mary lived in Westchester County in the state of New York. She was hospitalized in March 2015 and died in July of that year. The Xarelto bleeding lawsuit was filed by Plaintiff Sandra B. as a representative of her estate.
Xarelto is an anticoagulant or blood thinner. Drugs like this maker it harder to form blood clots, which can protect against conditions where blood clots form in the body and block the blood supply to vital organs.
However, patients taking anticoagulants carry the risk of the drugs working too well, resulting in uncontrolled bleeding. The Xarelto bleeding lawsuit alleges that Xarelto carries special risks that made it more dangerous than similar drugs.
Xarelto has no specific reversal agent. Older anticoagulants like Warfarin have known antidotes or reversal agents. This means that if patients taking the drug suffer internal bleeding or other forms of uncontrollable bleeding, doctors can use a second drug to “turn off” the drug. Drugmakers are scrambling to develop reversal agents for Xarelto and other later-generation anticoagulants.
This Xarelto lawsuit alleges that drugmakers were aware—or reasonably should have been aware—of the risk of Xarelto bleeding. The Xarelto bleeding lawsuit states that postmarket reports and peer-reviewed research illustrated the risk of Xarelto bleeding.
The Xarelto bleeding lawsuit holds that the drugmakers’ actions were negligent and fraudulent, and that prompting Xarelto over older drugs allegedly led to the injuries and deaths.
Under US law, drugmakers are legally obligated to review medical research and reports of complications reported in FDA surveillance databases for signs that their drugs are having unforeseen consequences.
The Xarelto lawsuit seeks to recoup costs stemming from injuries, pain and suffering and wrongful death allegedly caused by Xarelto. The Xarelto bleeding lawsuit also seeks to recoup legal fees and other costs related to the case, as well as have the court award survivors and next of kin punitive damages.
Punitive damages are a type of settlement money that goes above and beyond compensating victims. Punitive damages are designed to punish offenders and discourage further misconduct.
U.S. law strictly limits the circumstances in which punitive damages. However, drugs over allegedly defective drugs and medical devices are one of the few cases where plaintiffs are allowed to seek punitive damages.
The mass action against Xarelto argues that drugmakers have committed fraud and negligence, making them liable for the deaths and injuries allegedly caused by Xarelto.
The Xarelto Bleeding Lawsuit is Case No. 2592, filed in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/292476-xarelto-bleeding-lawsuit-filed-over-internal-bleeding-death/
-
Xarelto Bleed Injury Timeline 2016, Lawsuit Updates, and Patient Information
Jan 15, 2016 | Lieff Cabraser Heimann & Bernstein
By Lieff Cabraser
Xarelto Multidistrict Litigation - Case Update
The Xarelto multidistrict bellwether litigation is moving forward in the U.S. District Court in the Eastern District of Louisiana. The Court asked the parties in late December 2015 to select pool cases, which selection was completed January 11, 2016. The Court also requested that the chosen cases reflect multiple Xarelto injury categories, including gastrointestinal bleed and gi bleeding, brain bleeding events, hemorrhages, and hemorrhagic strokes. The Court is expected to select additional cases for inclusion originating in multiple states. The first trials are set for early February 2017 in Louisiana, with subsequent trials to occur in Mississippi and Texas in April and May 2017.
Xarelto was released in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use was then expanded to include patients with irregular heartbeats or facing likely lung and leg blood clots. It was also used to prevent clots in some people with atrial fibrillation. The drug is taken as a pill with the chemical name rivaroxaban. The new Xarelto patient information injury and lawsuit timeline shown below tracks Xarelto from its release to thousands of patient injury reports less than two years later, to thousands of Xarelto death and uncontrolled bleeding injury lawsuits slated for bellwether treatment in 2016 and 2017.
Contact Lieff Cabraser
Lieff Cabraser represents injured patients prescribed Xarelto in lawsuits charging Xarelto is a dangerous and defective drug because in some patients it triggers irreversible uncontrolled bleeding and other life-threatening complications. Xarelto (rivaroxaban) is sold in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson ("J&J"). Our law firm has been recognized by U.S. News, Best Lawyers, and The National Law Journal as one of the top plaintiffs' law firms in the nation. Pleasecontact us by completing our contact form or by calling us toll-free at 1 888-321-1510.
http://www.lieffcabraser.com/blog/2016/01/xarelto-bleed-injury-timeline-2016-lawsuit-updates-and-patient-information.shtml
-
Jan 17, 2016 | Law Office of J. Chrisp
When it comes to medication, patients generally take what is prescribed hoping for a quick recovery or remedy for their pain or illness. We don’t usually expect to find out our medication is defective. When this happens, patients who are treated with defective drugs can often seek compensation for their pain and suffering and other damages stemming from using the medication. Although this can occur with a wide variety of medications on the market, Xarelto is one that may require the assistance of a lawyer in California.
Xarelto Treatment
Xarelto, or its generic name Rivaroxaban, is a blood thinner intended to prevent blood clots from forming or to treat deep vein thrombosis which can lead to pulmonary embolism. Many times these types of clots occur after surgeries such as knee or hip replacement. Xarelto is also used to help patients with heart rhythm disorders to decrease the risk of stroke. Because of the risk of severe side effects and complications, there are strict guidelines that patients must follow while taking Xarelto.
Complications of Xarelto
As with any drug, it’s important that Xarelto is prescribed and managed under the care of a physician. However, there are additional complications that can occur which extend further than the normal side effects, that have led to numerous lawsuits against the manufacturer. Some of these complications are as follows.
Uncontrolled bleeding near major organs
Formation of pools of blood in the body
Severe health risks
Hemorrhaging
Easy bruising
Heavy menstrual periods
Bleeding that will not stop
If you are taking Xarelto and have experienced any of these or other complications, you need to seek medical care and consult a qualified lawyer to help you seek compensation for the damages.
Seeking Compensation for Defective Drugs
Whether it’s Xarelto, another anticoagulant drug, or one of many other defective drugs on the market, you deserve to receive the treatment you expect. If there’s a possibility your illness or injuries have been caused by a defective drug, you might be entitled to compensation. Compensation for defective drugs like Xarelto can help you manage the short-term and long-term effects the drug has on you and your family. However, defective drug lawsuits are complex and often lengthy, requiring the expertise of a lawyer familiar with the industry. Further, you have to keep in mind that you aren’t just battling the stress and pain caused by the drug, but you could also end up facing a major drug manufacturer. You need a lawyer on your side who can navigate the process for you and make sure you receive what you deserve.
Can a Lawsuit Help Me?
Very few patients are excited about the idea of filing a lawsuit against a large corporation, and most would just prefer to live without the pain the drug caused. However, if you are injured due to someone else’s negligence, even by a drug like Xarelto that was supposed to help you, a lawsuit may be necessary.
If you or a family member has been prescribed Xarelto and encountered complications, contact The Law Offices of J. Chrisp online or call 1-877-J-CHRISP (1-877-524-7477) immediately.
http://www.chrisplaw.com/product-liability/defective-drugs/xarelto/
-
Jan 18, 2016 | Schmidt National Law Group
The main risk associated with Xarelto (rivaroxaban) is uncontrolled bleeding, so employing some effective Xarelto bleeding precautions is of paramount importance for all patients taking this medication. If you are taking Xarelto to treat or prevent any condition such as Atrial Fibrillation (AFib), Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), or as a prophylaxis against stroke and blood clots, you should be adequately warned about the risks associated with this medication. Depending on what your condition is, you may need to take Xarelto for a defined period (usually for 2-6 weeks) or indefinitely for the rest of your life. Always read through the drug label information to know all the side effects and contraindications of this medication, and check with your doctor or pharmacist in case of any symptom of Xarelto side effects.
However, a few simple Xarelto bleeding precautions could be used to minimize the risks associated with this drug, such asXarelto uncontrolled bleeding, hemorrhoidal bleeding, gum bleeding, gastrointestinal bleeding or internal hemorrhages. All patients should be wary about even the smallest Xarelto bleeding: the lack of a proper Xarelto bleeding reversal method (antidote) could transform even a simple knife cut into a hemorrhage, requiring emergency intervention. This guide will provide you some basic information on how to reduce the risk of Xarelto bleeding.
https://xareltolawsuits.net/xarelto-bleeding-precautions/
-
Xarelto: The Impending Investigations
Jan 18, 2016 | Xarelto Lawyer
For patients who have experienced medical conditions that required being prescribed blood thinners, the results have been less than stellar. In fact, many times the results have been catastrophic. According to the Food and Drug Administration, the latest figures show over 2,000 Xarelto patients have experienced complications. With more than 200 deaths having been directly attributed to Xarelto complications, more legal experts familiar with the situation are now expecting an influx of lawsuits from numerous states, such as Florida and Vermont. In recent months, a Florida man died of a subdural hemorrhage, while a Vermont patient died from uncontrolled bleeding after taking Xarelto for only 10 days.
Based on these figures, it's expected Xarelto will become the most-sued pharmaceutical in history, surpassing another of the blood thinners, Pradaxa. As of now, there are more than 4,000 lawsuits against Xarelto, with roughly $650 million having been paid out in various settlements. But within two years, most legal experts predict a tremendous number of adverse effects concerning Xarelto will be reported, resulting in even more lawsuits being filed. According to consumer watchdog groups, the FDA has in recent months began assembling information that will be used to compile an updated report concerning new variances of complications. Once this report is published and made available to the public, the number of legal cases will possibly triple within three years.
Based on the sharp increase in lawsuits, the FDA is now convening a group of outside experts to take a closer look at just how the clinical trial data was submitted to the agency by Johnson and Johnson. According to those familiar with the upcoming analysis, the FDA is expected to focus intently on parts of the data that supposedly showed there was a growing medical need for the product. However, multiple applications submitted by Johnson and Johnson were initially rejected due to not having sufficient clinical data, which has been a fact that has remained hidden from the public and those patients and families filing lawsuits against the manufacturer.
As the investigation into Xarelto and its manufacturer takes yet another unexpected turn, those who have been affected by the drug are expected to closely watch the proceedings. While there appears to have been numerous attempts to either hide information or provide false information in order to gain quick approval, the FDA has assembled a team that is expected to take a very strong stance on the issue. If the agency comes down on the side of the patients, it's expected the number of lawsuits will increase to well over 5,000 within the next three years at most. If this happens, the drug's manufacturer will have even more questions to answer.
http://xareltolawyer.com/articles/xarelto-the-impending-investigations/
-
Finally a Xarelto Antidote seems to be a reality
Jan 21, 2016 | Schmidt National Law Group
Almost three hundreds of Xarelto lawsuits have been filed up to now. The amount of plaintiffs who seek the help of a Xarelto attorney to ask for compensation from Janssen Pharmaceutical and Bayer AG just reached over 2,800 cases. The huge and ever-growing number of Xarelto lawsuits has been recently consolidated in a Multidistrict Litigation MDL No. 2592 in the Eastern District of Louisiana, overseen by Judge Eldon Fallon.
Many people suffered several degrees of injury (including death) because of the dangerous Xarelto side effects. Probably the most dreaded adverse reaction of the infamous blood thinner is the Xarelto uncontrolled bleeding accident. The absence of a proper Xarelto antidote to reverse the medication’s effects did, in fact, prevent doctors and health carers from saving many patients lives. Even a simple Xarelto gastrointestinal bleeding or Xarelto gum bleeding may have dire consequences to the patient’s health, as once the bleeding occurs, there’s no way to stop it.
However, there’s a chance things are going to change. Portola Pharmaceuticals recently his new Xarelto bleeding reversal drug, an antidote called Andexanet Alfa (PRT064445). The medication was originally ideated to reverse the effects of another new generation blood thinner, Eliquis, but it may work even as a possible Xarelto antidote. Many doctors are afraid of using Xarelto to prevent stroke and blood clots in patients suffering from atrial fibrillation, but the availability of a new Xarelto bleeding reversal method may improve the medication’s safety profile. Andexanet Alfa is expected to be released on the markt this year, if the US Food and Drugs Administration grants its approval.
The new Xarelto Antidote may further increase the blood thinner’s potential market over its counterpart Warfarin, a 40 years old drug. However, Portola is also developing a new blood thinner medication to compete with Pradaxa, Eliquis and Xarelto.
https://xareltolawsuits.net/uncategorized/finally-a-xarelto-antidote-seems-to-be-a-reality/
-
Researchers Question Results of Clinical Trial Used to Approve Xarelto
Jan 21, 2016 | The Legal Examiner
By Eric T. Chaffin
The FDA first approved Xarelto (rivaroxaban) on July 1, 2011. A few months later, Thomas M. Burton, writing for the Wall Street Journal, noted that though the drug had been approved, it was despite the fact that FDA staff had found flaws in the clinical studies submitted by the manufacturer.
The FDA often establishes expert panels to submit recommendations on drug approvals. In the case of Xarelto, the panel voted 9-2 in favor, with one abstention, despite the administration’s concerns. According to Burton, the FDA often agrees with its expert panels, but “Xarelto is an unusual case because a strong majority of the panel disagreed with the FDA staff’s conclusions.”
In fact, one FDA staff reviewer stated that in the clinical trials, warfarin—the leading anticoagulant for decades—wasn’t skillfully used, which could have swayed the results to make Xarelto look better.
New information suggests that the expert panel made a mistake in not taking the FDA staff’s concerns about Xarelto more seriously. According to a recent report published in the British Medical Journal, researchers warn that a defective blood clotting test device used during the Xarelto clinical trials may have affected the results, and the European Medicines Agency (EMA) is now investigating the issue.Defective Device Could Have Skewed Results
The question is whether the defective device may have impacted the clotting results in some patients during a part of the study that compared Xarelto with warfarin. So far, manufacturers have been advertising Xarelto as a superior alternative to warfarin, with similar effectiveness and risk, yet more convenience. Plaintiffs who have filed Xarelto lawsuits claim the warning labels were inadequate, particularly when it comes to the risk of excessive bleeding.
The device is called INRatio (international normalized ratio), and measures how quickly blood starts clotting. Researchers reviewed the results, and then adjusted how much medication patients were receiving accordingly. If the blood was clotting too quickly, the patients needed more; if the blood was too “thin,” they needed less.
This particular INRatio is manufactured by Alere. The device was recalled back in December 2014 after reports indicated it was giving falsely low results. The FDA also sent two warning letters to Alere in 2006 about the device before the Xarelto study began.
The clinical study under examination is the ROCKET-AF study, which concluded that Xarelto and warfarin had comparable effectiveness, and comparable rates of excessive bleeding. If the INRatio was giving false results, however, it could be that patients in the clinical trial were given too much warfarin, which would mean that the drugs were not compared equally.
“Relative to warfarin, which would have more bleeding than it should, [Xarelto] would look better in terms of intracranial hemorrhage,” said Sidney Wolfe of the consumer advocacy group Public Citizen.Bayer Defends Xarelto Clinical Trial Outcomes
The possibility that the results of the INRatio test used could be faulty, yet was used in a clinical trial that was instrumental in the drugs approval has many concerned, because it could mean that some patients are more at risk of Xarelto bleeding than was previously understood. The Project on Government Oversight (POGO) states that the Duke Clinical Research Institute is conducting an independent analysis of the trial data to check for any potential effect the defective test may have had on the study results, and on certain population groups.
A member of the FDA advisory panel that reviewed Xarelto in 2011 stated that he was not aware of the FDA warning letters sent to Alere concerning the device, and that the panel should have had access to that information.
Manufacturer Bayer has defended the results of its clinical trial and stated that it conducted analyses that confirmed the results of ROCKET-AF, which showed that Xarelto was similar in effectiveness to warfarin, without significantly increasing risk of bleeding.
http://newyork.legalexaminer.com/defective-dangerous-products/researchers-question-results-of-clinical-trial-used-to-approve-xarelto/
-
Xarelto Blood Thinner MDL Reaches 2,400 Lawsuits
Jan 22, 2016 | Top Class Actions
By Ashley Vanover
Blood thinner lawsuits alleging patients suffered serious and life-threatening internal bleeding events after using the blood thinner Xarelto show no signs of slowing down, with 2,400 Xarelto lawsuits now pending in the multidistrict litigation.
Plaintiffs similarly allege that the blood thinner can cause dangerous uncontrollable bleeding episodes and that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals neglected to properly warn about the risks associated with the lack of available antidote for the blood thinner.
According to court documents, the Judicial Panel for Multidistrict Litigation (JPML) noted that as of Dec. 15, 2015, there were 2,400Xarelto blood thinner lawsuits consolidated for pretrial proceedings in MDL No. 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before U.S. District Judge Eldon E. Fallon).
In mid-October, the MDL lawsuits numbered nearly 1,700. Xarelto lawsuit lawyers expect the litigation will continue to grow as time goes on.
Xarelto Lawsuit Allegations
Xarelto was released and approved for sale in 2011 and touted as a superior replacement for Warfarin. Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.
Xarelto blood thinner lawsuits center on allegations that the drug makers failed to warn that the new blood thinner medication lacked an antidote to the drug’s anticlotting mechanism. Without an antidote to clot blood, someone who has Xarelto in their system can be at risk for developing uncontrollable bleeding after even a minor injury.
In these instances, doctors have to use extreme, life-saving measures like blood transfusions or surgery. Even after these attempts, patients can suffer from too much blood loss and die.
Other traditional anticoagulants, like warfarin, do not have this problem. When warfarin patients experience internal bleeding, an antidote in the form of vitamin K can counter the effects of the medication and allow blood to clot.
Many Xarelto lawsuits allege that had patients been made aware of the lack of Xarelto bleeding antidote, they would not have used the medication.
One of these recent lawsuits was filed jointly by nine plaintiffs from across the United States over injuries allegedly sustained in connection to the popular new blood thinner. Injuries include severe internal bleeding and ultimately resulted in the wrongful death of one of the plaintiff’s wife.
“Plaintiffs bring this case against Defendants for damages associated with ingestion of the pharmaceutical drug Xarelto,” the lawsuit states. “Specifically, Plaintiffs suffered various injuries, serious pain and suffering, medical, hospital and surgical expenses, loss of consortium, and/or death and funeral expenses as a direct result of their use of Xarelto.”
Xarelto Multidistrict Litigation
Since December 2014, all federal blood thinner lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.
The MDL in Louisiana now contains over 2,400 federal lawsuits, and the mass tort in Philadelphia contains more than 500 state lawsuits.
Judge Fallon set a series of four bellwether trials scheduled to go trial in Spring 2017.
As Xarelto lawsuit lawyers continue to lay the groundwork for the multidistrict litigation, the number of Xarelto lawsuits filed against the makers of the drug is expected to surpass the current 2,400 cases. If you or your loved one suffered from Xarelto bleeding, an experienced Xarelto lawsuit lawyer can evaluate your case and explain your legal options at no cost.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/300797-xarelto-blood-thinner-lawsuits-reach-2400-in-mdl/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
Add recipients
Suggested